NASDAQ:PTPI Petros Pharmaceuticals (PTPI) Stock Price, News & Analysis $0.05 0.00 (-8.55%) As of 02:28 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About Petros Pharmaceuticals Stock (NASDAQ:PTPI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Petros Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.05▼$0.0550-Day Range$0.04▼$0.2952-Week Range$0.04▼$0.77Volume5.46 million shsAverage Volume29.86 million shsMarket Capitalization$2.63 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPetros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.Read More… Petros Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScorePTPI MarketRank™: Petros Pharmaceuticals scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Petros Pharmaceuticals. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Petros Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Petros Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPetros Pharmaceuticals has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Petros Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.90% of the float of Petros Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPetros Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Petros Pharmaceuticals has recently increased by 98.58%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPetros Pharmaceuticals does not currently pay a dividend.Dividend GrowthPetros Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.90% of the float of Petros Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPetros Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Petros Pharmaceuticals has recently increased by 98.58%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A Search Interest7 people have searched for PTPI on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Petros Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Petros Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.25% of the stock of Petros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.34% of the stock of Petros Pharmaceuticals is held by institutions.Read more about Petros Pharmaceuticals' insider trading history. Receive PTPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Petros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PTPI Stock News HeadlinesPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple IndicationsMarch 20, 2025 | finanznachrichten.dePetros Pharmaceuticals enters collaboration with big data, analytics firmMarch 20, 2025 | msn.comElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.April 23, 2025 | Colonial Metals (Ad)Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal StudyFebruary 27, 2025 | finanznachrichten.dePetros Pharmaceuticals announces top-line results of expanded App Comp studyFebruary 25, 2025 | markets.businessinsider.comPetros Pharmaceuticals prices 40M shares at 24c in public offeringFebruary 18, 2025 | markets.businessinsider.comPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and WarrantsFebruary 18, 2025 | finanznachrichten.dePetros Pharmaceuticals files to sell units, no amount givenJanuary 25, 2025 | markets.businessinsider.comSee More Headlines PTPI Stock Analysis - Frequently Asked Questions How have PTPI shares performed this year? Petros Pharmaceuticals' stock was trading at $0.3939 on January 1st, 2025. Since then, PTPI shares have decreased by 87.3% and is now trading at $0.0499. View the best growth stocks for 2025 here. When did Petros Pharmaceuticals' stock split? Petros Pharmaceuticals's stock reverse split on the morning of Wednesday, November 30th 2022. The 1-10 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Petros Pharmaceuticals? Shares of PTPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Petros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Petros Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Bank of America (BAC), Abbott Laboratories (ABT), Cricut (CRCT) and JPMorgan Chase & Co. (JPM). Company Calendar Today4/23/2025Next Earnings (Estimated)5/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTPI CIK1815903 Webwww.petrospharma.com Phone973-242-0005FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,160,000.00 Net MarginsN/A Pretax Margin-117.50% Return on Equity-78.22% Return on Assets-23.50% Debt Debt-to-Equity Ratio1.58 Current Ratio0.85 Quick Ratio0.74 Sales & Book Value Annual Sales$5.11 million Price / Sales0.52 Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book0.01Miscellaneous Outstanding Shares53,519,000Free Float9,932,000Market Cap$2.67 million OptionableNot Optionable Beta2.17 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:PTPI) was last updated on 4/23/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.